{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:42:14Z","timestamp":1792168934435,"version":"4.4.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan Babcock Endowment Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AR071384"],"award-info":[{"award-number":["R01-AR071384"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AR069071"],"award-info":[{"award-number":["R01-AR069071"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008456","name":"A. Alfred Taubman Medical Research Institute Parfet Emerging Scholar Award","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008456","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kenneth and Frances Eisenberg Emerging Scholar Award"},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation Career Development K Supplement Award","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006510","name":"Doris Duke Physician Scientist Development Award","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.cyto.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T11:38:34Z","timestamp":1544096314000},"page":"154605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["The influence of interferon on healthy and diseased skin"],"prefix":"10.1016","volume":"132","author":[{"given":"Grace A.","family":"Hile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michelle","family":"Kahlenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"31","key":"10.1016\/j.cyto.2018.11.022_b0010","doi-asserted-by":"crossref","first-page":"20869","DOI":"10.1074\/jbc.M109.002923","article-title":"Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family","volume":"284","author":"Gad","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12010","article-title":"IFN-\u03b1 subtypes: distinct biological activities in anti-viral therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.11206","article-title":"Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis","volume":"49","author":"Alexiades-Armenakas","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.cyto.2018.11.022_b0025","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.cyto.2018.11.022_b0035","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"43","key":"10.1016\/j.cyto.2018.11.022_b0040","doi-asserted-by":"crossref","first-page":"39765","DOI":"10.1074\/jbc.M102502200","article-title":"Interferon-\u03ba, a novel type I interferon expressed in human keratinocytes","volume":"276","author":"LaFleur","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"Feb","key":"10.1016\/j.cyto.2018.11.022_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.11.013","article-title":"Human keratinocytes restrict chikungunya virus replication at a post-fusion step","volume":"476","author":"Bernard","year":"2015","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.cyto.2018.11.022_b0050","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/jid.2008.96","article-title":"An IFN-associated cytotoxic cellular immune response againstviral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis\u201d","volume":"128","author":"Wenzel","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0055","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.4049\/jimmunol.1501658","article-title":"CD28 deficiency enhances type I IFN production by murine plasmacytoid dendritic cells","volume":"196","author":"Macal","year":"2016","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0060","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4049\/jimmunol.177.1.298","article-title":"TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response","volume":"177","author":"Renn","year":"2006","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0065","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.39987","article-title":"Ultraviolet B irradiation causes stimulator of interferon genes-dependent production of protective type I interferon in mouse skin by recruited inflammatory monocytes","volume":"69","author":"Sontheimer","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.cyto.2018.11.022_b0070","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.4049\/jimmunol.0902314","article-title":"Major differences in the responses of primary human leukocyte subsets to IFN-beta","volume":"185","author":"van Boxel-Dezaire","year":"2010","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0075","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1046\/j.1365-2133.2003.05287.x","article-title":"Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis","volume":"148","author":"Baker","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cyto.2018.11.022_b0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yadr.2008.09.004","article-title":"Toll-like receptors in skin","volume":"24","author":"Miller","year":"2008","journal-title":"Adv. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0085","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.4049\/jimmunol.181.4.2694","article-title":"Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5\/RIG-I-mediated differential signaling","volume":"181","author":"Kalali","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.jid.5700530","article-title":"Human keratinocytes express functional toll-like receptor 3, 4, 5, and 9","volume":"127","author":"Lebre","year":"2007","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2016.09.008","article-title":"Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop","volume":"137","author":"Stannard","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0100","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.jid.5701087","article-title":"IFN-\u03b1 enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis","volume":"128","author":"Prens","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jdermsci.2012.02.006","article-title":"Characterization of retinoic acid-inducible gene-I (RIG-I) expression corresponding to viral infection and UVB in human keratinocytes","volume":"66","author":"Kimura","year":"2012","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0110","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1159\/000366359","article-title":"Expression and function of RIG-I in oral keratinocytes and fibroblasts","volume":"34","author":"Ohta","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"issue":"21","key":"10.1016\/j.cyto.2018.11.022_b0115","doi-asserted-by":"crossref","first-page":"10735","DOI":"10.1128\/JVI.01305-08","article-title":"Vaccinia virus subverts a mitochondrial antiviral signaling protein-dependent innate immune response in keratinocytes through its double-stranded RNA binding protein, E3","volume":"82","author":"Deng","year":"2008","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.cyto.2018.11.022_b0120","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/annrheumdis-2018-212988","article-title":"Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus","volume":"77","author":"Kato","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cyto.2018.11.022_b0125","doi-asserted-by":"crossref","first-page":"14392","DOI":"10.1038\/ncomms14392","article-title":"IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes","volume":"13","author":"Almine","year":"2017","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0130","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1128\/JVI.02137-15","article-title":"Interferon kappa inhibits human papillomavirus 31 transcription by inducing Sp100 proteins","volume":"90","author":"Habiger","year":"2015","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091473","article-title":"E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-kappa transcription in keratinocytes","volume":"9","author":"Sunthamala","year":"2014","journal-title":"PLoS ONE"},{"issue":"30","key":"10.1016\/j.cyto.2018.11.022_b0140","doi-asserted-by":"crossref","first-page":"47777","DOI":"10.18632\/oncotarget.10013","article-title":"Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin","volume":"7","author":"Lulli","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.cyto.2018.11.022_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102227","article-title":"The MEK inhibitors trametinib and cobimetinib induce a type I interferon response in human keratinocytes","volume":"18","author":"Lulli","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cyto.2018.11.022_b0150","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/exd.13253","article-title":"JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus","volume":"26","author":"Klaeschen","year":"2017","journal-title":"Exp. Dermatol."},{"issue":"8","key":"10.1016\/j.cyto.2018.11.022_b0155","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1128\/JVI.79.8.4838-4847.2005","article-title":"Constitutive expression of alpha interferon by skin dendritic cells confers resistance to infection by foot-and-mouth disease virus","volume":"79","author":"Bautista","year":"2005","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0160","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00109-007-0199-9","article-title":"A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus","volume":"85","author":"Lee-Kirsch","year":"2007","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0165","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajmg.a.33359","article-title":"Familial Aicardi-Goutieres syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures","volume":"152A","author":"Dale","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"issue":"8","key":"10.1016\/j.cyto.2018.11.022_b0170","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1469-8749.2010.03727.x","article-title":"Intracerebral large artery disease in Aicardi-Goutieres syndrome implicates SAMHD1 in vascular homeostasis","volume":"52","author":"Ramesh","year":"2010","journal-title":"Dev. Med. Child Neurol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/507848","article-title":"Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p","volume":"79","author":"Lee-Kirsch","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0180","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2018.11.022_b0185","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1172\/JCI79100","article-title":"Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations","volume":"124","author":"Jeremiah","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0190","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.cyto.2018.11.022_b0195","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ng.373","article-title":"Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response","volume":"41","author":"Rice","year":"2009","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.cyto.2018.11.022_b0200","first-page":"839","article-title":"Recent advances in cytokines in cutaneous and systemic lupus erythematosus","volume":"38","author":"Mikita","year":"2011","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0205","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0210","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2133.2011.10479.x","article-title":"Interferon-alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus","volume":"165","author":"Zahn","year":"2011","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.jid.5700945","article-title":"Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis","volume":"128","author":"Wenzel","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.1721","article-title":"Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus","volume":"205","author":"Wenzel","year":"2005","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/ard.2007.070359","article-title":"Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients","volume":"67","author":"Reefman","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0230","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.21034","article-title":"Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus","volume":"52","author":"Meller","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.cyto.2018.11.022_b0235","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jid.2017.03.041","article-title":"STING is involved in antiviral immune response against VZV infection via the induction of type I and III IFN pathways","volume":"137","author":"Kim","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0240","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.4049\/jimmunol.1100857","article-title":"Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients","volume":"187","author":"Robinson","year":"2011","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2018.11.022_b0245","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/exd.12428","article-title":"Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus","volume":"23","author":"Zahn","year":"2014","journal-title":"Exp. Dermatol."},{"issue":"7","key":"10.1016\/j.cyto.2018.11.022_b0250","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jid.2017.03.016","article-title":"IL-21 may promote granzyme B-dependent NK\/plasmacytoid dendritic cell functional interaction in cutaneous lupus erythematosus","volume":"137","author":"Salvi","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.cyto.2018.11.022_b0255","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jid.2017.03.018","article-title":"Immunostimulatory endogenous nucleic acids drive the lesional inflammation in cutaneous lupus erythematosus","volume":"137","author":"Scholtissek","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0260","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.immuni.2013.08.004","article-title":"Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing","volume":"39","author":"Gehrke","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0265","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jdermsci.2010.05.002","article-title":"Regulation of epidermal keratinocytes by growth factors","volume":"59","author":"Shirakata","year":"2010","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0270","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/S0021-9258(17)42129-6","article-title":"Control of growth regulatory and differentiation-specific genes in human epidermal keratinocytes by interferon gamma. Antagonism by retinoic acid and transforming growth factor beta 1","volume":"269","author":"Saunders","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.cyto.2018.11.022_b0275","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/archderm.136.12.1497","article-title":"Detection of type 1 cytokines in discoid lupus erythematosus","volume":"136","author":"Toro","year":"2000","journal-title":"Arch. Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0280","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/BOR.0b013e3283585748","article-title":"Skin disease in dermatomyositis","volume":"24","author":"Zaba","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0295","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.cyto.2018.11.022_b0300","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0305","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/path.4346","article-title":"Altered RIG-I\/DDX58-mediated innate immunity in dermatomyositis","volume":"233","author":"Su\u00e1rez-Calvet","year":"2014","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0310","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1600-0560.2009.01443.x","article-title":"The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis","volume":"37","author":"Margo","year":"2010","journal-title":"J. Cutan. Pathol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0320","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"issue":"8","key":"10.1016\/j.cyto.2018.11.022_b0325","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1007\/s10067-006-0374-3","article-title":"Cutaneous findings in patients with primary Sjogren's syndrome","volume":"26","author":"Soy","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2018.11.022_b0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0335","first-page":"142","article-title":"The interferon-signature of Sj\u00f6gren\u2019s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases","volume":"5","author":"Nguyen","year":"2013","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0340","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jdcr.2017.04.011","article-title":"Cutaneous purpura of Sjogren syndrome successfully treated with hydroxychloroquine","volume":"3","author":"Hile","year":"2017","journal-title":"JAAD Case Rep."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0345","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/0961203313515764","article-title":"Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases","volume":"23","author":"Brito-Zeron","year":"2014","journal-title":"Lupus"},{"issue":"9997","key":"10.1016\/j.cyto.2018.11.022_b0350","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cyto.2018.11.022_b0355","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/jid.2014.28","article-title":"Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms","volume":"134","author":"Li","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0360","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10072-009-0184-x","article-title":"Psoriasis during interferon beta treatment for multiple sclerosis","volume":"31","author":"La Mantia","year":"2010","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0365","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1468-3083.2012.04582.x","article-title":"Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases","volume":"27","author":"Afshar","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0370","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0375","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/pde.13418","article-title":"Interferon-alpha induced psoriasis in a teenager","volume":"35","author":"Mendieta","year":"2018","journal-title":"Pediatr. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1440-0960.2004.00030.x","article-title":"Psoriasis induced by topical imiquimod","volume":"45","author":"Wu","year":"2004","journal-title":"Australas. J. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00128071-200607040-00006","article-title":"The role of antimalarials in the exacerbation of psoriasis: a systematic review","volume":"7","author":"Herman","year":"2006","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.cyto.2018.11.022_b0390","first-page":"3","article-title":"Exacerbation of psoriasis due to hydroxychloroquine","volume":"7","author":"McCoy","year":"2015","journal-title":"Arch. Med. Online"},{"issue":"9","key":"10.1016\/j.cyto.2018.11.022_b0395","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0400","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/ar3150","article-title":"Type I IFN and TNFalpha cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance","volume":"12","author":"Cantaert","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0405","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0410","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","article-title":"Immune signaling by RIG-I-like receptors","volume":"34","author":"Loo","year":"2011","journal-title":"Immunity"},{"issue":"51","key":"10.1016\/j.cyto.2018.11.022_b0415","doi-asserted-by":"crossref","first-page":"20446","DOI":"10.1073\/pnas.0810372105","article-title":"A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity","volume":"105","author":"Negishi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0420","doi-asserted-by":"crossref","first-page":"589","DOI":"10.15252\/emmm.201607027","article-title":"RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease","volume":"9","author":"Zhu","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"7128","key":"10.1016\/j.cyto.2018.11.022_b0425","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"7551","key":"10.1016\/j.cyto.2018.11.022_b0430","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.cyto.2018.11.022_b0435","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1093\/hmg\/ddr215","article-title":"Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis","volume":"20","author":"Bijlmakers","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0440","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/BJ20070995","article-title":"T-cell regulator RNF125\/TRAC-1 belongs to a novel family of ubiquitin ligases with zinc fingers and a ubiquitin-binding domain","volume":"410","author":"Giannini","year":"2008","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0445","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.jid.5701087","article-title":"IFN-alpha enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis","volume":"128","author":"Prens","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.cyto.2018.11.022_b0450","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/jid.2010.214","article-title":"Carriers of rare missense variants in IFIH1 are protected from psoriasis","volume":"130","author":"Li","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"21","key":"10.1016\/j.cyto.2018.11.022_b0455","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1093\/hmg\/ddx328","article-title":"Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling","volume":"26","author":"Dand","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0460","doi-asserted-by":"crossref","first-page":"25381","DOI":"10.1038\/srep25381","article-title":"Up-regulation of Interferon-inducible protein 16 contributes to psoriasis by modulating chemokine production in keratinocytes","volume":"3","author":"Cao","year":"2016","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.cyto.2018.11.022_b0465","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/jid.2012.149","article-title":"Type I IFNs at the interface between cutaneous immunity and epidermal remodeling","volume":"132","author":"Conrad","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0470","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.immuni.2016.06.021","article-title":"Antimicrobial peptide LL37 and MAVS signaling drive interferon-beta production by epidermal keratinocytes during skin injury","volume":"45","author":"Zhang","year":"2016","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0475","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1074-7613(00)00064-9","article-title":"CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha\/beta signaling","volume":"13","author":"Hida","year":"2000","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0480","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1346-8138.12367","article-title":"Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod","volume":"41","author":"Ueyama","year":"2014","journal-title":"J. Dermatol."},{"issue":"10","key":"10.1016\/j.cyto.2018.11.022_b0485","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jid.2016.06.608","article-title":"Therapeutic elimination of the type 1 interferon receptor for treating psoriatic skin inflammation","volume":"136","author":"Gui","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0490","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.0022-202X.2003.22113.x","article-title":"In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered","volume":"122","author":"van der Fits","year":"2004","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0495","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jir.1994.14.229","article-title":"The type I interferon system is locally activated in psoriatic lesions","volume":"14","author":"Schmid","year":"1994","journal-title":"J. Interferon Res."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0500","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/43.1.7822763","article-title":"Expression of MxA protein in inflammatory dermatoses","volume":"43","author":"F\u00e4h","year":"1995","journal-title":"J. Histochem. Cytochem."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0505","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.0022-202X.2004.22322.x","article-title":"Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers","volume":"122","author":"Suomela","year":"2004","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.cyto.2018.11.022_b0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002737","article-title":"Type I interferon: potential therapeutic target for psoriasis?","volume":"3","author":"Yao","year":"2008","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0515","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0520","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00403-004-0512-1","article-title":"The role of perforin-mediated apoptosis in lichen planus lesions","volume":"296","author":"Ka\u0161telan","year":"2004","journal-title":"Arch. Dermatol. Res."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0525","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1468-3083.2003.00583.x","article-title":"Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis","volume":"17","author":"de Sousa Pinto","year":"2003","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0530","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jdcr.2017.09.034","article-title":"Erosive oral lichen planus after pegylated-interferon therapy for chronic hepatitis B","volume":"4","author":"Choi","year":"2018","journal-title":"JAAD Case Rep."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0535","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cld.2017.03.010","article-title":"Dermatologic manifestations of chronic hepatitis C infection","volume":"21","author":"Sayiner","year":"2017","journal-title":"Clin. Liver Dis."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0540","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1365-2133.2009.09033.x","article-title":"Detection of myxovirus resistance protein A in lichen planus lesions and its relationship to hepatitis C virus","volume":"160","author":"Shaker","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cyto.2018.11.022_b0545","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mehy.2016.04.042","article-title":"Targeting the IFN-gamma\/CXCL10 pathway in lichen planus","volume":"92","author":"Di Lernia","year":"2016","journal-title":"Med. Hypoth."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0550","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","article-title":"Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation","volume":"194","author":"Flier","year":"2001","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0555","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bjd.13214","article-title":"The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7\/TLR8 and TLR9 ligands in cutaneous lichen planus","volume":"172","author":"Domingues","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0560","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2007.083246","article-title":"Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced?","volume":"68","author":"H\u00fcgle","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0565","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jdcr.2014.10.002","article-title":"Interferon beta-1a-induced morphea","volume":"1","author":"Bezalel","year":"2014","journal-title":"JAAD Case Rep."},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0570","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","article-title":"Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases","volume":"145","author":"Leitenberger","year":"2009","journal-title":"Arch. Dermatol."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0575","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1600-0625.2012.01475.x","article-title":"Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea","volume":"21","author":"Ghoreishi","year":"2012","journal-title":"Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0580","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2010.05.045","article-title":"Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis","volume":"64","author":"Fett","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.cyto.2018.11.022_b0585","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MOP.0000000000000375","article-title":"Understanding autoimmunity of vitiligo and alopecia areata","volume":"28","author":"Rork","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0590","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","article-title":"Alopecia areata: an evidence-based treatment update","volume":"15","author":"Hordinsky","year":"2014","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0595","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0600","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000065841","article-title":"Alopecia areata during interferon alpha-2b\/ribavirin therapy","volume":"205","author":"Agesta","year":"2002","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.cyto.2018.11.022_b0605","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1684\/ejd.2014.2421","article-title":"Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege","volume":"24","author":"Ito","year":"2014","journal-title":"Eur. J. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0610","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000353160","article-title":"Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin","volume":"228","author":"Patrk","year":"2014","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.cyto.2018.11.022_b0615","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000079904","article-title":"Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma?","volume":"209","author":"Radny","year":"2004","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0620","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MEG.0b013e32832be7a5","article-title":"A case of irreversible alopecia associated with ribavirin and peg-interferon therapy","volume":"22","author":"Shafa","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0625","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1179\/joc.2005.17.2.212","article-title":"Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C","volume":"17","author":"Taliani","year":"2005","journal-title":"J. Chemother."},{"issue":"9","key":"10.1016\/j.cyto.2018.11.022_b0630","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/MEG.0b013e32818b27e5","article-title":"Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection","volume":"19","author":"Kartal","year":"2007","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0635","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdv.12932","article-title":"Plasmacytoid dendritic cells in alopecia areata: missing link?","volume":"30","author":"Abou Rahal","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.cyto.2018.11.022_b0640","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1523-1747.2000.00828.x","article-title":"Role of cytotoxic T cells in chronic alopecia areata","volume":"114","author":"Bodemer","year":"2000","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0645","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1523-1747.2002.01811.x","article-title":"Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans","volume":"119","author":"Carroll","year":"2002","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0650","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/jid.2012.17","article-title":"Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse","volume":"132","author":"McPhee","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.cyto.2018.11.022_b0655","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","article-title":"The autoimmune basis of alopecia areata: a comprehensive review","volume":"14","author":"Islam","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.cyto.2018.11.022_b0660","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/exd.12489","article-title":"The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata","volume":"23","author":"Ito","year":"2014","journal-title":"Exp. Dermatol."},{"issue":"May","key":"10.1016\/j.cyto.2018.11.022_b0665","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ebiom.2016.03.036","article-title":"Molecular signatures define alopecia areata subtypes and transcriptional biomarkers","volume":"7","author":"Jabbari","year":"2016","journal-title":"EBioMedicine"},{"issue":"15","key":"10.1016\/j.cyto.2018.11.022_b0670","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"9988","key":"10.1016\/j.cyto.2018.11.022_b0675","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"223","key":"10.1016\/j.cyto.2018.11.022_b0680","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.cyto.2018.11.022_b0685","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br. J. Dermatol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346661830440X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346661830440X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:56:32Z","timestamp":1760907392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104346661830440X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":137,"alternative-id":["S104346661830440X"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2018.11.022","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The influence of interferon on healthy and diseased skin","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154605"}}